Logo image of AH.CA

Aleafia Health Inc (AH.CA) Stock Fundamental Analysis

TSX:AH - Toronto Stock Exchange - CA01444Q1046 - Common Stock - Currency: CAD

0.02  0 (0%)

Fundamental Rating

2

AH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AH have multiple concerns. AH shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AH had negative earnings in the past year.
AH had a negative operating cash flow in the past year.
AH had negative earnings in each of the past 5 years.
AH had a negative operating cash flow in each of the past 5 years.
AH.CA Yearly Net Income VS EBIT VS OCF VS FCFAH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

The profitability ratios for AH are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AH.CA Yearly ROA, ROE, ROICAH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

AH's Gross Margin of 21.35% is in line compared to the rest of the industry. AH outperforms 44.19% of its industry peers.
In the last couple of years the Gross Margin of AH has declined.
The Profit Margin and Operating Margin are not available for AH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-52.06%
GM growth 5Y-25.49%
AH.CA Yearly Profit, Operating, Gross MarginsAH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

AH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AH has been increased compared to 1 year ago.
Compared to 5 years ago, AH has more shares outstanding
The debt/assets ratio for AH is higher compared to a year ago.
AH.CA Yearly Shares OutstandingAH.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
AH.CA Yearly Total Debt VS Total AssetsAH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

AH has an Altman-Z score of -12.50. This is a bad value and indicates that AH is not financially healthy and even has some risk of bankruptcy.
AH's Altman-Z score of -12.50 is on the low side compared to the rest of the industry. AH is outperformed by 86.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.5
ROIC/WACCN/A
WACC4.33%
AH.CA Yearly LT Debt VS Equity VS FCFAH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 0.83 indicates that AH may have some problems paying its short term obligations.
AH has a worse Current ratio (0.83) than 74.42% of its industry peers.
AH has a Quick Ratio of 0.83. This is a bad value and indicates that AH is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.22, AH is not doing good in the industry: 86.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.22
AH.CA Yearly Current Assets VS Current LiabilitesAH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

AH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.40%, which is quite impressive.
AH shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.19%.
The Revenue has been growing by 61.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)79.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-138.84%
Revenue 1Y (TTM)52.19%
Revenue growth 3Y37.87%
Revenue growth 5Y61.75%
Sales Q2Q%33.46%

3.2 Future

AH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.32% yearly.
AH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.85% yearly.
EPS Next Y40%
EPS Next 2Y18.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year51.58%
Revenue Next 2Y31.85%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AH.CA Yearly Revenue VS EstimatesAH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AH.CA Yearly EPS VS EstimatesAH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AH.CA Price Earnings VS Forward Price EarningsAH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AH.CA Per share dataAH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1

4.3 Compensation for Growth

A more expensive valuation may be justified as AH's earnings are expected to grow with 18.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.32%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Aleafia Health Inc

TSX:AH (7/25/2023, 7:00:00 PM)

0.02

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners2.06%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.06M
Analysts40
Price Target0.15 (650%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-29.41%
Min Revenue beat(2)-38.79%
Max Revenue beat(2)-20.04%
Revenue beat(4)1
Avg Revenue beat(4)2.93%
Min Revenue beat(4)-38.79%
Max Revenue beat(4)92.17%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.14
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.35%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-52.06%
GM growth 5Y-25.49%
F-Score4
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.22
Altman-Z -12.5
F-Score4
WACC4.33%
ROIC/WACCN/A
Cap/Depr(3y)79.73%
Cap/Depr(5y)248.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-138.84%
EPS Next Y40%
EPS Next 2Y18.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)52.19%
Revenue growth 3Y37.87%
Revenue growth 5Y61.75%
Sales Q2Q%33.46%
Revenue Next Year51.58%
Revenue Next 2Y31.85%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year309.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.35%
OCF growth 3YN/A
OCF growth 5YN/A